Keryx Biopharmaceuticals Inc (KERX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Gregory P. Madison
Employees:
193
ONE MARINA PARK DR., BOSTON, MA 02210
617-466-3500

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Keryx Biopharmaceuticals, Inc. engages in the development and commercialization of medicines for the treatment of renal disease. Its products include phosphate-binding medicines, intravenous iron, and other medications. The company was founded in October 1998 and is headquartered in Boston, MA.

Data derived from most recent annual or quarterly report
Market Cap 343.983 Million Shares Outstanding102.376 Million Avg 30-day Volume 1.773 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-2.15
Price to Revenue31.4986 Debt to Equity0.0 EBITDA-33.382 Million
Price to Book Value2.6665 Operating Margin-358.9646 Enterprise Value217.946 Million
Current Ratio7.516 EPS Growth0.721 Quick Ratio6.953
1 Yr BETA 52-week High/Low 0.0 / Profit Margin-363.205
Operating Cash Flow Growth-45.7097 Altman Z-Score13.1882 Free Cash Flow to Firm -55.319 Million
View SEC Filings from KERX instead.

View recent insider trading info

Funds Holding KERX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding KERX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ROGERS MICHAEL W

  • Director
No longer subject to file 2018-12-12 0

GILMAN STEVEN C

  • Director
No longer subject to file 2018-12-12 0

CAMERON KEVIN J

  • Director
No longer subject to file 2018-12-12 0

HEFFERNAN MICHAEL THOMAS

  • Director
No longer subject to file 2018-12-12 0

HOLMES SCOTT A CHIEF FINANCIAL OFFICER

  • Officer
No longer subject to file 2018-12-12 0

REGAN DANIEL PAUL

  • Director
No longer subject to file 2018-12-12 0

ENYEDY MARK J

  • Director
No longer subject to file 2018-12-12 0

MORRISON JODIE POPE INTERIM CEO

  • Officer
  • Director
No longer subject to file 2018-12-12 0

NEYLAN JOHN F. CHIEF MEDICAL OFFICER

  • Officer
No longer subject to file 2018-12-12 0

BAUPOST GROUP LLC/MA

BAUPOST GROUP GP, L.L.C.

KLARMAN SETH A

  • Director
  • 10% Owner
No longer subject to file 2018-12-11 0

CARBERRY CHRISTINE A. CHIEF OPERATING OFFICER

  • Officer
No longer subject to file 2018-12-11 0

MADISON GREG PRESIDENT AND CEO

  • Officer
  • Director
566,586 2018-03-20 0

ADAMS BRIAN GENERAL COUNSEL AND SECRETARY

  • Officer
126,069 2018-02-15 0

BUTLER JOHN P.

  • Director
20,000 2017-06-09 0

BAUPOST GROUP LLC/MA

SAK CORP

KLARMAN SETH A

  • 10% Owner
42,016,276 2015-10-14 0

OLIVIERO JAMES F III CHIEF FINANCIAL OFFICER

  • Officer
209,406 2015-07-06 0

FECZKO JOSEPH M

  • Director
120,000 2015-06-17 0

KAYE JACK

  • Director
85,000 2015-06-17 0

FOWLER WYCHE JR

  • Director
No longer subject to file 2015-06-17 0

TARNOK MICHAEL P.

  • Director
338,600 2015-06-17 0

BENTSUR RON CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
777,209 2015-04-06 0

WEISS MICHAEL S

  • 10% Owner
No longer subject to file 2010-04-23 0

ROSE ERIC A MD

  • Director
155,000 2008-11-14 0

HOENLEIN MALCOLM

  • Director
110,000 2008-11-14 0

STIER MARK CHIEF ACCOUNTING OFFICER

  • Officer
0 2007-12-30 0

HENDERSON CRAIG PRESIDENT

  • Officer
  • Director
0 2007-12-30 0

LEVINE BETH F SVP, GC, CCO AND SECRETARY

  • Officer
0 2007-12-30 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments